Pancreatic Cancer Research

ResearcherCleveland ClinicActive in the last 2 years

Gauri Rajani Varadhachary

Verified by OpenAlex author ID and NIH RePORTER profile ID (good confidence, 0.85), identity_conf@1As of 6 November 2026

Matched on OpenAlex author ID A5113794025; NIH RePORTER profile ID 8932181. Sources: ClinicalTrials.gov.

Their work

Papers
82 (first author 4, last author 3)
Trials
3 (principal investigator on 3)
Grants
1
Labs led
1
Collaborators
204
Papers, trials and grants by year

2006: 1 trial · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 6 papers · 2012: 10 papers, 2 trials · 2013: 3 papers · 2014: 6 papers · 2015: 7 papers · 2016: 7 papers · 2017: 9 papers · 2018: 6 papers · 2019: 10 papers · 2020: 8 papers · 2021: 6 papers · 2022: 2 papers · 2023: 1 paper, 1 grant · 2024: none · 2025: 1 paper

Papers 50 of 82

  1. Engineered exosomes with Kras G12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Co-author DOI 10.1038/s41467-025-63718-2↗
  2. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline r… Co-author DOI 10.1136/jitc-2023-007586↗
  3. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreati… Co-author DOI 10.1016/j.ijrobp.2022.06.089↗
  4. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. Co-author DOI 10.1186/s12885-021-09095-7↗
  5. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Co-author DOI 10.1002/cam4.3870↗
  6. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.11.003↗
  7. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma… Co-author DOI 10.1016/s1470-2045(20)30532-5↗
  8. Characterisation of circulating tumour cell phenotypes identifies a partial-EMT sub-population for clinical stratification of pancreatic cancer. Co-author DOI 10.1038/s41416-021-01350-9↗
  9. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003442↗
  10. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. Co-author DOI 10.21037/jgo-20-569↗
  11. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2020.2286↗
  12. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3229↗
  13. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Co-author DOI 10.1016/j.pan.2020.01.005↗
  14. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003763↗
  15. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-0224↗
  16. The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08427-4↗
  17. Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study. Co-author DOI 10.3390/cancers12123656↗
  18. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unres… Co-author DOI 10.4103/eus.eus_44_19↗
  19. Borderline resectable pancreatic cancer-At the crossroads of precision medicine. First author DOI 10.1002/cncr.31936↗
  20. Physical activity and exercise during preoperative pancreatic cancer treatment. Co-author DOI 10.1007/s00520-018-4493-6↗
  21. Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. Co-author DOI 10.1016/j.vgie.2019.02.009↗
  22. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2018.09.022↗
  23. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Co-author DOI 10.1073/pnas.1811067116↗
  24. Expression and Clinical Significance of Protein Kinase RNA-Like Endoplasmic Reticulum Kinase and Phosphorylated Eukaryotic Initiation Factor 2α in Pancreatic D… Co-author DOI 10.1097/mpa.0000000000001248↗
  25. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIR… Co-author DOI 10.1097/mpa.0000000000001345↗
  26. Expression of Epithelial-Mesenchymal Transition Markers in Treated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001432↗
  27. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. Last author DOI 10.1200/po.19.00001↗
  28. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-018-6807-9↗
  29. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therap… Co-author DOI 10.1002/cncr.31251↗
  30. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. Co-author DOI 10.1093/annonc/mdx542↗
  31. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-3668↗
  32. High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer. Co-author DOI 10.1158/1940-6207.capr-18-0014↗
  33. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic… First author DOI 10.1186/s13045-018-0616-2↗
  34. Dynamic changes during the treatment of pancreatic cancer. Co-author DOI 10.18632/oncotarget.24483↗
  35. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2017.2227↗
  36. A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. Co-author DOI 10.1007/s00520-016-3553-z↗
  37. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Co-author DOI 10.1007/s11605-016-3265-1↗
  38. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? Co-author DOI 10.1016/j.ijrobp.2016.10.046↗
  39. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Co-author DOI 10.1093/annonc/mdx004↗
  40. Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. Co-author DOI 10.1097/mpa.0000000000000914↗
  41. Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy. Co-author DOI 10.1097/pas.0000000000000887↗
  42. Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0171985↗
  43. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Co-author DOI 10.18632/oncotarget.19897↗
  44. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.30117↗
  45. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. Co-author DOI 10.1007/s11605-016-3286-9↗
  46. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolida… Co-author DOI 10.1016/j.ijrobp.2015.12.003↗
  47. Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival. Co-author DOI 10.1097/pas.0000000000000738↗
  48. The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy. Co-author DOI 10.1111/his.12732↗
  49. Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy? Co-author DOI 10.1200/jop.2016.015586↗
  50. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. Co-author DOI 10.1371/journal.pone.0156910↗

Trials 3

  1. Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas Principal investigator NCT01560949↗
  2. Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy Principal investigator NCT01938716↗
  3. Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer Principal investigator NCT00416793↗

Grants 1

  1. Administrative Core P50CA221707↗

Closest collaborators

The 25 strongest of 204 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthew H. G. Katz · 65 shared papers, 2011–2023 · strength 3.98
  2. Robert A. Wolff · 60 shared papers, 2011–2022 · strength 3.64
  3. Anirban Maitra · 28 shared papers, 1 shared grant, 2014–2025 · strength 2.48
  4. Jeffrey E. Lee · 43 shared papers, 2011–2022 · strength 2.26
  5. Milind M. Javle · 32 shared papers, 2011–2022 · strength 2.01
  6. David R. Fogelman · 27 shared papers, 2011–2021 · strength 1.88
  7. Shubham Pant · 12 shared papers, 1 shared grant, 2019–2025 · strength 1.79
  8. Jason B. Fleming · 42 shared papers, 2011–2019 · strength 1.78
  9. Huamin Wang · 33 shared papers, 2012–2022 · strength 1.77
  10. Eugene Jon Koay · 21 shared papers, 2014–2022 · strength 1.55
  11. Michael James Overman · 19 shared papers, 2014–2022 · strength 1.47
  12. Rachna T. Shroff · 16 shared papers, 2014–2025 · strength 1.22
  13. Ching-Wei David Tzeng · 16 shared papers, 2012–2022 · strength 1.16
  14. Michael P. Kim · 13 shared papers, 2016–2022 · strength 1.06
  15. Priya Bhosale · 15 shared papers, 2012–2022 · strength 1.05
  16. Eric Peter Tamm · 15 shared papers, 2012–2022 · strength 1.05
  17. Laura R. Prakash · 14 shared papers, 2015–2021 · strength 1.05
  18. Christopher H. Crane · 23 shared papers, 2011–2022 · strength 0.98
  19. Joseph M. Herman · 10 shared papers, 2017–2021 · strength 0.80
  20. Sunil Krishnan · 13 shared papers, 2011–2022 · strength 0.68
  21. Hua Wang · 12 shared papers, 2012–2021 · strength 0.54
  22. Peter W. T. Pisters · 17 shared papers, 2011–2017 · strength 0.53
  23. Jean‐Nicolas Vauthey · 13 shared papers, 2012–2019 · strength 0.49
  24. Naruhiko Ikoma · 5 shared papers, 2020–2022 · strength 0.49
  25. Mohamed Zaid · 6 shared papers, 2018–2022 · strength 0.48

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.